Schering-Plough to evaluate Peg-Intron in combined disease (Hepatitis C Infection)

Schering-Plough to evaluate Peg-Intron in combined disease
Pharmaceutical Business Review - Jan 16 6:10 PM
Schering-Plough is set to initiate a large multinational clinical trial to evaluate the use of low-dose Peg-Intron maintenance monotherapy in patients who are infected with both hepatitis C and HIV.Save to My Web

Schering-Plough Initiates PEGINTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV
FinanzNachrichten - Jan 12 11:47 PM
Schering-Plough ( Nachrichten / Aktienkurs ) announced today that it is initiating a large multinational clinical trial to evaluate the use of low-dose PEGINTRON(R) (peginterferon alfa-2b) maintenance monotherapy in preventing or delaying hepatitis C disease progression and thus potentially reducing the occurrence of clinical events such as liver transplantation, liver cancer and death in Save to My Web

GlobeImmune Secures Additional $4.1 Million and Closes Series B Financing With a Total of $38.4 Million Raised
[Press Release] PR Newswire via Yahoo! Finance - Jan 10 1:16 PM
GlobeImmune, Inc. today announced the final closing of a Series B Preferred Stock financing. GlobeImmune added an additional $4.1 million to the previously-announced first close of $34.3 million, bringing the total amount raised in the Series B financing to $38.4 million.Save to My Web

Novartis and Idenix seek European approval of telbivudine (LDT600) for the ...
Financial.de - Feb 07 1:04 AM
Basel, February 7, 2006 - Novartis ( News / Kurs / Chart / Board ) and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than three million people in Europe1 and over 350 million people worldwide.Save to My Web

Hepatitis C Recurs Rapidly After Liver Transplant
Science Daily - Feb 06 3:41 PM
When a diseased liver is removed from a patient with Hepatitis C (HCV), serum viral levels plummet. However, after receiving a healthy liver transplant, virus levels rebound and can surpass pre-transplant levels within a few days, according to a new study.Save to My Web